These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 20189920)
1. Hand-foot syndrome related to liposomal doxorubicin. Swenson KK; Bell EM Oncol Nurs Forum; 2010 Mar; 37(2):137-9. PubMed ID: 20189920 [No Abstract] [Full Text] [Related]
2. "Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome". Von Moos R; Cathomas R Eur J Dermatol; 2009; 19(3):264-5. PubMed ID: 19213658 [No Abstract] [Full Text] [Related]
3. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868 [TBL] [Abstract][Full Text] [Related]
4. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience. Rossi D; Catalano G Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894 [No Abstract] [Full Text] [Related]
5. ["Hand-foot" syndrome--after liposomal pegylated doxorubicin in patients with the ovarian cancer recurrence (own experiences)]. Mrochen-Domin I; Nowara E; Kaleta B Ginekol Pol; 2008 May; 79(5):332-7. PubMed ID: 18624107 [TBL] [Abstract][Full Text] [Related]
6. [Liposomal doxorubicin and palmoplantar erythrodysesthesia]. Tomb R; Stephan F; Halaby G Ann Dermatol Venereol; 2003 Nov; 130(11):1057-8. PubMed ID: 14724543 [No Abstract] [Full Text] [Related]
7. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity. Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744 [TBL] [Abstract][Full Text] [Related]
9. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin. Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932 [TBL] [Abstract][Full Text] [Related]